Health Reform And Legislation

Alec Morton of NUS explains how AI is changing health technology assessment, what stays human, and why cheaper analysis could mean more health economics.

The European Commission's EU Public Procurement Act would make quality, not price, the default for public tenders. EFPIA supports the shift, with one warning: resilience should not become local-content rules. #SyenzaNews #EUProcurement #Medicines #MarketAccess #HealthPolicy

South Korea is putting AI at the centre of its healthcare agenda, pairing the new AI Basic Healthcare Strategy with a USD 30.4 billion biohealth export target. Vice Minister Lee Hyung Hoon sets out the vision in an interview with PharmaBoardroom. #SyenzaNews #SouthKorea #Biohealth #DigitalHealth #MarketAccess

The United States has added nine more manufacturers to its most-favored-nation drug pricing program, taking the total to 26 companies that now cover 89% of the branded drug market. #MarketAccess #DrugPricing #Pharma

Insurers are spending billions on breakthrough medicines, but the tests that decide who gets them are still an afterthought. Kathryn Phillips lays out four reforms to link drug and diagnostic policy pathways. #SyenzaNews #diagnostics #healtheconomics #MarketAccess

🔑 How is South Africa’s SEP adjustment safeguarding pharma supply security? The latest Single Exit Price adjustment seeks to balance affordability with manufacturer sustainability, helping to stabilise medicine availability amid economic pressures. Read the full analysis to see what it means for pricing, supply chains and market access. #SyenzaNews #pharmaceuticals #regulatoryaffairs #MarketAccess #healthcarepolicy

South Africa's drugmakers and the health department are at odds over lowest-price tenders. Pharmisa says cheaper imports have cost more than 2,500 jobs and eroded local manufacturing capacity.

How are cell therapies redefining cancer care through rigorous HTA evaluation? INCA’s latest analysis highlights how CAR-T and other advanced cell therapies are shifting oncology paradigms—balancing innovation with evidence-based access and cost-effectiveness. Explore the full breakdown and its implications for global cancer treatment. #SyenzaNews #oncology #precisionmedicine #innovation #MarketAccess

🚀 What sparked China's pharmaceutical innovation surge after 2016? Key regulatory reforms streamlined approvals and accelerated R&D, rapidly elevating the country’s role in global drug development. Explore the data and trends behind this transformation. #SyenzaNews #pharmaceuticals #drugdevelopment #innovation #MarketAccess

What happens when Medicare Part D subsidies end? Beneficiaries could see modest premium increases next year as federal support phases out, potentially shifting more costs to seniors and affecting prescription drug affordability across the U.S. Explore the latest analysis on these changes and their market implications. #SyenzaNews #healthcare #HealthEconomics #healthcarepolicy #costeffectiveness

📊 How is Portugal turning hospital data into powerful population health insights? A new data platform is enabling deeper analysis of health trends, outcomes, and resource use across patient populations. Explore how this approach is advancing data-driven decision-making in healthcare. #SyenzaNews #digitalhealth #HealthTech #DigitalTransformation #datascience

Could transatlantic reference pricing reshape drug innovation and global market strategy? 🔍 This article examines how cross‑Atlantic reference pricing proposals could compress prices, alter launch sequencing, and force pharmaceutical companies to rethink R&D investment and pricing strategies—impacting patient access and international equity. It outlines the likely risks, strategic responses, and policy trade‑offs for industry, payers, and regulators. Read the full analysis to see what this means for your organization and next steps. #SyenzaNews #pharmaceuticals #HealthEconomics #MarketAccess #costeffectiveness